Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2018 | Story Leonie Bolleurs | Photo Leonie Bolleurs
One step closer to treat HIV/Aids
Nthabiseng Mokoena is working on an article based on her research about drug development in infection models, which will be published under the Research Chair in Pathogenic Yeasts.

South Africa has the biggest and most high-profile HIV epidemic in the world, with an estimated seven million people living with HIV in 2015. In the same year, there were 380 000 new infections while 180 000 South Africans died from AIDS-related illnesses. 

Invasive fungal infection, common in certain groups of patients with immune deficits, is a serious driver of global mortality in the context of the global HIV pandemic. 

“Despite a major scientific effort to find new cures and vaccines for HIV, hundreds of thousands of HIV-infected individuals continue to die on a yearly basis from secondary fungal infection. Intensive research needs to be done to help reduce the unacceptably high mortality rate due to the infection in South Africa,” said Nthabiseng Mokoena.

Mokoena is a master’s student of Prof Carlien Pohl-Albertyn, who is heading the Research Chair in Pathogenic Yeasts in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS). 

She received her master’s degree at the December graduations of the UFS. Her thesis is titled: Caenorhabditis elegans as a model for Candida albicans-Pseudomonas aeruginosa co-infection and infection induced prostaglandin production.

Research Chair in Pathogenic Yeasts

Earlier this year, the National Research Foundation approved the Research Chair in Pathogenic Yeasts. One of the projects of the group of scientists in this chair include a study of the interaction between the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa in different hosts, using a variety of infection models.

In her research, Mokoena studied the response of infectious pathogens such as yeasts and bacteria, using a nematode (little roundworm) as an infection model to mimic the host environment. Nematodes have a number of traits similar to humans. It is thus a good alternative for humans as infection models, as it is unethical to use the latter.

Nematodes have a number of advantages, including its low cost and fast reproduction and growth. 

Mokoena monitored the survival of the nematodes to see how infectious the pathogens are, especially in combination with each other. 

Role of infection model for drug development

When these two pathogens were studied in a lab (in vitro), it was found that they can inhibit each other, but after studying them in the infection model (in vivo), Mokoena showed that these pathogens are more destructive together. 

This finding has a huge impact for the pharmaceutical industry, as it can provide information on how drugs need to be designed in order to fight infectious diseases where multiple organisms cause co-infections.

Many pathogens are resistant to drugs. Through this model, drugs can be tested in a space similar to the human body. Seeing how pathogens react to drugs within a space similar to the human body, can contribute to drug development. 

Not only are drugs developed more effectively through this model, it is also less expensive. 

It is the first time that the combination of the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa, is being experimented on in this model. 

News Archive

SA women’s Hockey players give a recount of Hockey World League
2015-07-02

Nicole Walraven and Liné Malan
Photo: Hatsu Mphatsoe

Three of the star players of Kovsies Hockey formed part of the South African Women’s Hockey team, which competed at the Hockey World League (HWL) tournament in Spain.

Hatsu Mphatsoe, student assistant at the Department of Communication and Brand Management, spoke to Nicole Walraven and Liné Malan. Tanya Britz will be returning only at a later stage to South Africa.

As key players in the Kovsies women’s team, Malan and Walraven (along with Britz) have a new wealth of knowledge that could assist the team in their forthcoming USSA tournament. Here are some of the sentiments they had to share:

What was your reaction when you first received the news that you’d be representing the country in Spain?

Liné: “It was a shock to me, I honestly didn’t expect it. At the same time, I was extremely excited to be granted the opportunity to represent my country, and prove my worth to the team.”

Nicole: “I was so excited and felt honoured! To represent my country at such a big tournament is amazing. I was very nervous, but excited.”

How has playing at an international level improved your personal performance and mentality of the game/sport?

Nicole: “Playing at such a high level has helped my hockey immensely. It has helped me read the game better, it has upped my self-confidence, and it has also improved my ability to deal with pressure.”

Liné: “Playing at an international level looks much easier than it is. It is a much faster game, the pressure on the ball is much higher, and the individual skills are on a different level. It has helped me to lift my game, and make decisions much quicker. It has honestly benefitted me as an individual, and I’ve learnt so much from the experience.”

Now that you’ll be going to play at the USSA tournament, what new perspectives do you wish to bring to the team in order to improve its overall performance there?

Nicole: “The importance of teamwork as well as adapting the game plan according to the situation and the opposition. Constant hard work and a never-give-up attitude are vital. One quote that stood out from the tournament is ‘1MT, 1MT’ which stands for ‘1 More Thing, 1 More Time’.

Liné: “Going to USSA, I now have a better understanding of what pressure is, and how to make better decisions. We will still make use of our Kovsies brand of Hockey, which is our passing game, and apply all aspects to the best of our ability.”

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept